Drugs & Targets FDA OCE annual report lists 83 cancer therapeutic approvals in 2023 February 23, 2024Vol.50 No.08
Drugs & Targets Mainz Biomed and Praxisdienst form distribution partnership for ColoAlert February 23, 2024Vol.50 No.08
Black History MonthConversation with The Cancer Letter University of Maryland’s Owonikoko: What it means to be a Black director of an NCI-designated cancer center February 16, 2024Vol.50 No.07By Amy Lacey, Otis W. Brawley and Paul Goldberg
Capitol Hill Delay in passing the FY24 budget is “disastrous for our cancer centers” February 16, 2024Vol.50 No.07By Alexandria Carolan
Guest Editorial Patient navigation, financial toxicity top the agenda as Jill Biden, Kimryn Rathmell visit Atrium Health Wake Forest February 16, 2024Vol.50 No.07By Ruben A. Mesa
Guest Editorial SABCS: 46 years at the forefront of clinical and translational research in breast cancer—and still growing February 16, 2024Vol.50 No.07By Virginia Kaklamani, Srivani Ravoori and Carlos L. Arteaga
In Brief Steven Rosenberg to receive 2024 AACR Award for Lifetime Achievement in Cancer Research February 16, 2024Vol.50 No.07
In Brief James Allan named chair of Foundation for Biomedical Research board of directors February 16, 2024Vol.50 No.07
